These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 6151221)

  • 1. Inhibition of transglutaminase by hypoglycaemic sulphonylureas in pancreatic islets and its possible relevance to insulin release.
    Gomis R; Mathias PC; Lebrun P; Malaisse-Lagae F; Sener A; Malaisse WJ
    Res Commun Chem Pathol Pharmacol; 1984 Dec; 46(3):331-49. PubMed ID: 6151221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulphonylureas do not increase insulin secretion by a mechanism other than a rise in cytoplasmic Ca2+ in pancreatic B-cells.
    Garcia-Barrado MJ; Jonas JC; Gilon P; Henquin JC
    Eur J Pharmacol; 1996 Mar; 298(3):279-86. PubMed ID: 8846827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
    Ikenoue T; Akiyoshi M; Fujitani S; Okazaki K; Kondo N; Maki T
    Br J Pharmacol; 1997 Jan; 120(1):137-45. PubMed ID: 9117089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase activity in pancreatic islets.
    Gomis R; Sener A; Malaisse-Lagae F; Malaisse WJ
    Biochim Biophys Acta; 1983 Nov; 760(3):384-8. PubMed ID: 6138101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function.
    Gregorio F; Ambrosi F; Cristallini S; Pedetti M; Filipponi P; Santeusanio F
    Diabetes Res Clin Pract; 1992 Dec; 18(3):197-206. PubMed ID: 1289021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition.
    Fujitani S; Okazaki K; Yada T
    Br J Pharmacol; 1997 Apr; 120(7):1191-8. PubMed ID: 9105692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of transglutaminase in insulin release. Study with glycine and sarcosine methylesters.
    Sener A; Dunlop ME; Gomis R; Mathias PC; Malaisse-Lagae F; Malaisse WJ
    Endocrinology; 1985 Jul; 117(1):237-42. PubMed ID: 2408879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic, cationic and secretory effects of hypoglycemic sulfonylureas in pancreatic islets.
    Kawazu S; Sener A; Couturier E; Malaisse WJ
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jul; 312(3):277-83. PubMed ID: 6995864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose modulates the amount, but not the kinetics, of insulin released by sulfonylureas.
    Gregorio F; Ambrosi F; Filipponi P; Cristallini S; Santeusanio F
    J Diabetes Complications; 1994; 8(4):204-12. PubMed ID: 7833495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental study of glipizide. A comparison with other hypoglycemic sulfonamides (author's transl)].
    Loubatières AL; Loubatieres-Mariani MM; Alric R; Ribes G; Sorial G; Tarasco A
    Diabete Metab; 1975 Mar; 1():13-21. PubMed ID: 824163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression by 2-ketoisocaproate of the insulinotropic action of hypoglycemic sulfonylureas.
    Malaisse WJ; Mathias PC; Malaisse-Lagae F; Sener A
    Res Commun Chem Pathol Pharmacol; 1985 Feb; 47(2):265-84. PubMed ID: 3922019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interacting effects of sulfonylureas and glucose on cyclic AMP metabolism and insulin release in pancreatic islets of the rat.
    Grill V; Cerasi E
    J Clin Invest; 1978 May; 61(5):1346-54. PubMed ID: 207736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of a calcium-agonist and hypoglycemic or hyperglycemic sulfonamides upon insulin release.
    Malaisse WJ; Sener A; Malaisse-Lagae F
    Res Commun Chem Pathol Pharmacol; 1985 Jul; 49(1):71-83. PubMed ID: 3898259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of cellular actions between gliclazide and a hypoglycaemic peptide fragment of human growth hormone (hGH 6-13).
    Ng FM
    Diabetes Res Clin Pract; 1988 May; 5(1):17-24. PubMed ID: 3042343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibition of glucose-stimulated insulin secretion by primary amines. A role for transglutaminase in the secretory mechanism.
    Bungay PJ; Potter JM; Griffin M
    Biochem J; 1984 May; 219(3):819-27. PubMed ID: 6146312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the cationic and secretory response of pancreatic islets to gliclazide and/or potassium.
    Mathias PC; Billaudel B; Malaisse WJ
    Res Commun Chem Pathol Pharmacol; 1983 Dec; 42(3):389-400. PubMed ID: 6320319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for transglutaminase in glucose-stimulated insulin release from the pancreatic beta-cell.
    Bungay PJ; Owen RA; Coutts IC; Griffin M
    Biochem J; 1986 Apr; 235(1):269-78. PubMed ID: 2874792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylamine and islet function: possible relationship to Ca2+-sensitive transglutaminase.
    Sener A; Gomis R; Lebrun P; Herchuelz A; Malaisse-Lagae F; Malaisse WJ
    Mol Cell Endocrinol; 1984 Jul; 36(3):175-80. PubMed ID: 6147286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of sulfonylurea-induced insulin release from the isolated perfused rat pancreas.
    Gotfredsen CF
    Diabetologia; 1976 Aug; 12(4):339-42. PubMed ID: 134920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and secretory effects of methylamine in pancreatic islets.
    Gomis R; Deleers M; Malaisse-Lagae F; Sener A; Garcia-Morales P; Rovira A; Valverde I; Malaisse WJ
    Cell Biochem Funct; 1984 Jul; 2(3):161-6. PubMed ID: 6148157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.